This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Corneal Disorders  • Glaucoma  • Ophthalmological Disorders, Other  • Statistics and Research Methods  • Women's Health  • Women's Health, Other  • Alert me on articles by topic

James D. Brandt, MD

Arch Ophthalmol. 2008;126(8):1138-1139.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Glaucoma is in the midst of a paradigm shift, moving from the somewhat static staging of the disease to a more evidence-based risk assessment of the individual patient. This shift applies both to patients with confirmed glaucoma and to those at risk of developing the disease, be they individuals with ocular hypertension or those suspected of having glaucoma on some other basis. Other medical specialties have for years provided individualized risk assessments to their patients based on solid evidence from the laboratory and clinical trials. For example, oncologists have long been able to prognosticate using histopathology and clinical factors. More germane to glaucoma, however, is the field of cardiovascular medicine, in which well-designed population-based surveys and clinical trials have led to widely accepted models of cardiovascular disease risk. These models of risk, simple enough to be deployed as a slide rule, checklist, or Web site, can . . . [Full Text of this Article]

AUTHOR INFORMATION